Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction PD-1 Blockade in Locally Advanced dMMR Solid Tumors
NCT04165772Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2019
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab in solid tumor, endometrial cancer (EC), rectal adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2019; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
solid tumorendometrial cancer (EC)rectal adenocarcinoma
Beyond the preview
Go deeper on NCT04165772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165772.